MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$9,186M
(14.34%↑ Y/Y)
Europe
$5,040M
(-1.23%↓ Y/Y)
International Markets
$2,162M
(-12.22%↓ Y/Y)
Other Activities
$870M
(-7.84%↓ Y/Y)
Net revenues
$17,258M
(4.32%↑ Y/Y)
Gross profit
$8,938M
(10.84%↑ Y/Y)
Cost of sales
$8,320M
(-1.90%↓ Y/Y)
Operating income (loss)
$2,157M
(811.88%↑ Y/Y)
Adjustments to valuation
allowances on deferred tax...
$187M
Selling and marketing
expenses
$2,686M
(5.71%↑ Y/Y)
General and
administrative expenses
$1,287M
(10.85%↑ Y/Y)
Other asset
impairments, restructuring...
$1,050M
(-24.35%↓ Y/Y)
Research and development
expenses, net
$1,013M
(1.50%↑ Y/Y)
Legal settlements and
loss contingencies
$467M
(-38.63%↓ Y/Y)
Intangible assets
impairments
$259M
(3.19%↑ Y/Y)
Other loss (income)
-$18M
(-228.57%↓ Y/Y)
Adjustments to valuation
allowances on deferred tax...
$138M
Changes in unrecognized
tax benefits...
$60M
Adjustments to valuation
allowances on deferred tax...
$40M
Statutory tax rate
difference (amount)-Malta...
$34M
Other (amount)-Malta
Tax Authority
$6M
Other (amount)-Swiss
Federal Tax...
$4M
Income (loss) before
income taxes
$1,223M
(195.25%↑ Y/Y)
Income taxes (benefit)
-$180M
(-126.63%↓ Y/Y)
Share in (profits)
losses of associated...
$15M
(1400.00%↑ Y/Y)
Financial expenses net
-$934M
(4.79%↑ Y/Y)
Statutory tax rate
difference (amount)-Swiss...
-$162M
Reduced rate due to
imputation system...
$89M
Adjustments to valuation
allowances on deferred tax...
-$33M
Other
(amount)-Revenue Commissioners...
-$4M
Other (amount)-Tax
And Customs...
-$1M
Net income (loss)
$1,418M
(172.38%↑ Y/Y)
Net income (loss)
attributable to teva
$1,410M
(186.03%↑ Y/Y)
Net income (loss)
attributable to redeemable...
$7M
(102.19%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
logo_teva-svg
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
logo_teva-svg
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)